Please assess the completion status of the following clinical trial:

Trial Title: Effect of Saxagliptin on EPCs as a Cellular Biomarker for Evaluating Endothelial Dysfunction in Early T2DM Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~1. Adults aged 40-70 years.~2. Diagnosis of type 2 diabetes within the previous 8 years using criteria of the American Diabetes Association~3. Currently treated with no hypoglycemic agents other than a stable dose (\>3 months) of metformin (≥1.0 to ≤2 grams daily).~4. HbA1C between 6 to 9% (both inclusive)~5. BMI 25 to 39.9 kg/m2 (both inclusive)~Exclusion Criteria:~1. Contraindications for moderate exercise~2. Implanted devices (e.g., pacemakers) that may interact with Tanita scale~3. Previous coronary or cerebrovascular event within 6 months of screening or active or clinically significant coronary and/or peripheral vascular disease.~4. Low hematocrit \<28 Units~5. Pre-existing liver disease and/or ALT and AST \>2.5X's UNL~6. Kidney disease (serum creatinine levels ≥1.5 mg/dL for men, ≥1.4 mg/dL for women,Creatinine Clearance ≤50 mL/min)~7. History of pancreatitis, or cancer (except basal cell carcinoma)~8. Statin use started (or dose change) in the last 3 months.~9. Use of oral or injectable anti-diabetic medication other than Metformin~10. Use of any form of consistent-long term steroid medication (oral, inhaled injected or nasal) within the last 3 months~11. Systolic BP\> 140 mmHg and diastolic BP\> 90 mmHg~12. Active wounds or recent surgery within 3 months.~13. Inflammatory disease, or current use of anti-inflammatory drugs~14. triglycerides \>400 mg/dL~15. untreated hyper/hypothyroidism Additionally, patients who are active smokers, patients who are pregnant, nursing women, and post menopausal women who are on hormone replacement therapy will be excluded.~Patients on low dose oral contraceptives will be allowed to participate as these formulations contain lesser amount of estrogens.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Matching placebo 1 pill daily for 12 weeks
- saxagliptin (Type: ACTIVE_COMPARATOR): Saxagliptin 5mg once daily for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).